Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster lunch

1713 - Efficacy and safety of CapeIRI plus bevacizumab therapy as a second-line treatment for the patients with metastatic colorectal cancer. (149P)

Date

18 Nov 2017

Session

Poster lunch

Topics

Cytotoxic Therapy;  Colon and Rectal Cancer

Presenters

Yuki Sunagawa

Citation

Annals of Oncology (2017) 28 (suppl_10): x42-x56. 10.1093/annonc/mdx659

Authors

Y. Sunagawa, G. Nakayama, N. Hattori, K. Ezaka, H. Uda, S. Umeda, B. Sato, S. Yamada, H. Sugimito, M. Koike, Y. Kodera

Author affiliations

  • Gastroenterological Surgery, Nagoya University, Graduate School of Medicine, 466-8550 - Nagoya/JP
More

Resources

Abstract 1713

Background

There have been few reports of CapeIRI plus bevacizumab (BEV) for treatment of patients with metastatic colorectal cancer (mCRC). The objectives of this study was to evaluate the efficacy and safety of CapeIRI plus BEV therapy as a second-line setting for the mCRC patients treated with oxaliplatin-based chemotherapy combined with BEV therapy.

Methods

This was a multicenter, single-armed phase II study in Japan. The primary endpoint was progression-free survival (PFS), and the secondary objectives included overall survival (OS), objective response rate (ORR), disease control rate (DCR), and safety.

Results

After a median follow-up period of 14.2 months, the disease progressed in 29 patients (96.7%) and 22 deaths (73.3%) occurred in the 30 patients enrolled. The median PFS and OS were 6.4 months (95%CI 3.7-9.1) and 17.0 months (95%CI 9.5-18.4), respectively. The ORR and DCR were 11.5% and 88.5%, respectively. The incidence of hematological and non-hematological adverse events above grade three were 22.6% and 19.4%, respectively.

Conclusions

CapeIRI plus bevacizumab therapy is a feasible second-line treatment for Japanese patients with mCRC.

Clinical trial identification

Legal entity responsible for the study

Chubu Clinical Oncology Group

Funding

None

Disclosure

All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.